Yashoda Hospital, Hitech City, in collaboration with Qure.ai and AstraZeneca, has launched an AI-enabled Lung Nodule Clinic to support earlier identification and timely management of lung cancer and other pulmonary diseases.
Back
Lung cancer is one of the leading causes of cancer-related deaths in India¹. Most patients are diagnosed at an advanced stage because early disease often has no symptoms and is easily missed on routine imaging². A large proportion of cases in India present late, which limits the chances of curative treatment². India does not have a national lung cancer screening program for high-risk individuals³, which makes structured imaging pathways an important way to support earlier detection.
Pulmonary nodules are often subtle findings that can vary in size, density, and location, which makes them challenging to identify consistently on routine chest imaging. The new Lung Nodule Clinic at Yashoda Hospital, Hitech City, integrates Qure.ai’s AI solutions into chest X-ray workflows to flag, risk assess, and track these findings in a structured manner. Nodules can be indicators of early lung cancer or other conditions such as tuberculosis, sarcoidosis, or lymphoma. The AI-supported pathway helps clinicians prioritise higher-risk cases and ensure timely and consistent follow-up.
“This program shows how AI can be integrated into clinical workflows to support earlier identification and structured management of lung disease,” said Dr. V. Nagarjuna Maturu, Head of Department, Pulmonology, Yashoda Hospital, Hitech City. “The pathway ensures that incidental findings are consistently tracked and followed up. Embedding AI into routine workflows has helped Yashoda Hospital create a scalable model for proactive lung health. This shows how coordinated use of data and clinical expertise can improve real-world diagnosis and outcomes.”
A nurse navigator model supports the system and helps patients move from AI flagging to counselling, review, and next steps. “Standardised workflows help avoid delays and ensure consistent communication and documentation,” added Dr. Vipul Garg, lead Consultant, Yashoda Hospitals Nodule Clinic.
Since deployment, more than 17,000 chest X-rays have been analysed using Qure.ai’s AI. The program has identified over 960 nodules. Of these, 136 were classified as high risk and 77 patients were sent for expedited CT scans and pulmonology review. Confirmed diagnoses include lung cancers as well as other significant lung diseases, highlighting the broader value of this pathway for proactive lung health.
“AI is becoming an important part of how health systems strengthen early diagnosis and reduce the burden of late stage lung disease,” said Sagar Sen, Vice President, Life Sciences, Qure.ai. “By integrating intelligence into routine imaging, hospitals can turn everyday X-rays into an opportunity for earlier detection and more coordinated care. The Lung Nodule Clinic at Yashoda Hospital is a strong example of how technology and clinical expertise can work together to create a more proactive approach to lung health.”
The AI supported pathway represents an important move toward structured, data driven lung health and demonstrates the role of modern diagnostic tools in improving early detection in high volume hospital settings.
